ANDA 202456, held by Zydus Pharmaceuticals (USA). Pioglitazone Hydrochloride.
As of Nov 21, 2026, ANDA 202456 (Pioglitazone Hydrochloride), held by Zydus Pharmaceuticals (USA), was first approved by FDA on Feb 13, 2013, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 13, 2013 | Original application | Approved | None posted |
| Pioglitazone HydrochlorideEQ 15MG BASE · tablet;oral | Pioglitazone Hydrochloride | Rx |
| Pioglitazone HydrochlorideEQ 30MG BASE · tablet;oral | Pioglitazone Hydrochloride | Rx |
| Pioglitazone HydrochlorideEQ 45MG BASE · tablet;oral | Pioglitazone Hydrochloride | Rx |
| Nov 26, 2018 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 26, 2018 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 26, 2018 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 13, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters